Horizon Technology Finance Corp is a specialty finance company... Show more
Horizon Technology Finance Corporation is an externally managed business development company (BDC) headquartered in Farmington, Connecticut. It specializes in providing secured loans and venture-debt financing to venture capital-backed, growth-stage companies across the technology, life science, healthcare information and services, and sustainability sectors. The company earns income primarily from interest and fees on its loan portfolio, which is heavily weighted toward debt investments.
Following its April 2026 merger with Monroe Capital Corporation (MRCC), Horizon operates as an affiliate of Monroe Capital, a move that expanded its capital base and lending capacity. Investors follow HRZN largely for its substantial monthly distributions and its exposure to the venture-debt market, a niche that benefits from private company funding demand while carrying meaningful credit risk.
Over the last 30 days, HRZN fell from $4.62 on October 2, 2026, to $4.07 by the October 30 close, a decline of approximately 11.9%. The move accelerated in the second half of October, when the stock dropped from $4.59 on October 15 to below $4.10 within a few sessions before stabilizing near $4.07.
The quarterly picture is similar but slightly less severe. Over the trailing three months, HRZN declined roughly 10%, from around $4.50 in early August to $4.07 in late October. That decline came after a sharp mid-August rally that briefly carried the stock above $5.10, meaning the stock gave back nearly all of its third-quarter gains and returned to the lower portion of its 52-week trading range.
Several factors combined to pressure HRZN over the past month. The most concrete near-term driver was the October 16 ex-dividend date, when the stock traded without its $0.09 monthly distribution (a $0.06 regular payment plus a $0.03 special payment). While ex-dividend adjustments are mechanical and normally small, the stock's decline extended well beyond the distribution amount, indicating additional selling pressure.
Broader concerns about distribution coverage and portfolio credit quality also weighed on sentiment. HRZN's second-quarter results, reported in early August, showed net investment income of $0.11 per share against a $0.13 consensus, alongside write-downs tied to a single portfolio company. Commentary in the income-investing community has highlighted declining net asset value (NAV) and payouts that outstrip earnings, which can make a high headline yield less durable than it appears.
Positioning ahead of the company's third-quarter earnings report, scheduled for November 5, 2026, likely added to the cautious tone as investors reduced risk before a key update on net investment income, NAV, and portfolio performance.
Over the past three months, HRZN's path was defined by a rally followed by a retreat. Shares climbed from about $4.30 in late July to an intra-quarter peak above $5.10 in mid-August, supported by post-merger enthusiasm following the Monroe Capital combination and by the company's stated intent to distribute accumulated "spillover" income through special dividends.
That momentum faded as investors refocused on fundamentals. The second-quarter earnings miss and the write-down of a single portfolio investment renewed scrutiny of credit quality and the sustainability of distributions. From mid-August through late October, the stock ground lower in a series of lower highs, ultimately erasing the quarter's earlier gains and settling near $4.07. The result was a roughly 10% decline for the quarter, with the downside concentrated in September and October.
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI-powered trading bots. Tickeron offers hundreds of automated bots that trade across thousands of tickers, but only the top-performing and most relevant strategies are featured in this section. The bots vary by trading style, timeframe, and performance metrics, allowing traders to filter for approaches that match their own objectives. For investors tracking income-oriented and financial-sector names, these tools provide an additional, data-driven lens on momentum and positioning. Exploring the section can help identify automated strategies currently drawing attention across the market.
The most important near-term catalyst is the third-quarter 2026 earnings release, scheduled for November 5, 2026. Investors will focus on net investment income per share, NAV per share, portfolio credit quality, and any change to the distribution or spillover-income outlook.
Beyond earnings, several themes matter for HRZN's direction. Distribution coverage relative to net investment income remains central, as does the pace of new loan originations and the company's ability to deploy capital from its expanded, post-merger platform. Macroeconomic conditions also play a role: interest-rate levels influence both portfolio yields and borrowing costs, while venture-debt demand and defaults across technology and life science borrowers shape credit performance. Finally, any further analyst rating or price-target changes will signal how Wall Street interprets the company's earnings and dividend trajectory.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +5.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRZN advanced for three days, in 150 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 48%.
HRZN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HRZN as a result. In 45 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 60%.
The Moving Average Convergence Divergence Histogram (MACD) for HRZN turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 23 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
The 50-day moving average for HRZN moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
The Aroon Indicator for HRZN entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. HRZN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.636) is normal, around the industry mean (2.423). P/E Ratio (10.703) is within average values for comparable stocks, (8.341). Projected Growth (PEG Ratio) (1.907) is also within normal values, averaging (1.318). Dividend Yield (0.091) settles around the average of (0.274) among similar stocks. P/S Ratio (11.062) is also within normal values, averaging (15.906).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRZN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a closed-end investment trust
Industry InvestmentManagers